-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, D0d55ZecGB4IP7vJSpe21X+SRsGZk24flrIGurYvPwmbcLSzwCgOHdWClEyA/ZxL y/cNWu3Vg2UNKqN2HcgB8A== 0001144204-07-001267.txt : 20070110 0001144204-07-001267.hdr.sgml : 20070110 20070110142548 ACCESSION NUMBER: 0001144204-07-001267 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20070108 ITEM INFORMATION: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20070110 DATE AS OF CHANGE: 20070110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CELLEGY PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000887247 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 820429727 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-26372 FILM NUMBER: 07522902 BUSINESS ADDRESS: STREET 1: 2085?B? QUAKER POINT DRIVE CITY: QUAKERTOWN STATE: PA ZIP: 18951 BUSINESS PHONE: 215-529-6084 MAIL ADDRESS: STREET 1: 2085?B? QUAKER POINT DRIVE CITY: QUAKERTOWN STATE: PA ZIP: 18951 8-K 1 v062303.htm Unassociated Document
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of report (Date of earliest event reported): January 8, 2007
 
 
 Cellegy Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
 
 
 
 
 
 
 
Delaware
 
0-26372
 
82-0429727
(State or other jurisdiction
of incorporation)
 
(Commission File Number)
 
(IRS Employer
Identification No.)
 
 
 
 
2085B Quaker Point Drive
Quakertown, Pennsylvania
 
18951
(Address of Principal Executive Offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code: (215) 529-6084
 
 
 
(Former name or Former Address, if Changed Since Last Report.) 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 


Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 
 
On January 8, 2007, the compensation committee of the board of directors of Cellegy Pharmaceuticals, Inc., approved a reduction in the rate of compensation payable to Richard C. Williams, the company’s Interim Chief Executive Officer. The reduction, which Mr. Williams proposed, reduces his rate of monthly compensation from $40,000 per month to $25,000 per month, effective January 6, 2007. The reduction will continue for a period of three months, and the committee and Mr. Williams may evaluate compensation rates for subsequent periods.
 
Item 9.01. Financial Statements and Exhibits.
 
(d) Exhibits.

None.

 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.  
 
 
 
 
 
 
 
CELLEGY PHARMACEUTICALS, INC.
 
 
 
 
 
 
Date: January 10, 2007
By:  
/s/ Robert J. Caso
 
Robert J. Caso
 
Vice President, Finance
(Duly Authorized Officer)
 

 -----END PRIVACY-ENHANCED MESSAGE-----